Navigation Links
Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
Date:10/15/2009

EAST BRUNSWICK, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a result, Savient sold a total of 4,945,000 shares of its common stock at a price to the public of $13.29 per share. After underwriting discounts and commissions and estimated offering expenses, Savient received net proceeds of approximately $60.9 million. These shares were sold pursuant to Savient's existing shelf registration statement, the prospectus contained therein and the prospectus supplement as filed with the Securities Exchange Commission.

Savient intends to use the net proceeds from this offering to complete its effort to seek FDA approval of KRYSTEXXA(TM) (pegloticase), to develop a program of regulatory filings and review of KRYSTEXXA in other countries, to engage a global secondary source supplier and a secondary fill and finish manufacturer for pegloticase, and for working capital and other general corporate purposes.

J.P. Morgan Securities Inc. acted as sole book-running manager of the offering, with Wedbush PacGrow Life Sciences as lead manager and Lazard Capital Markets as co-manager. Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

SVNT -G

SOURCE Savient Pharmaceuticals, Inc.


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
2. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Savient Provides Update on Pegloticase BLA
4. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
5. Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback
6. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
7. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
8. China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results
9. VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
10. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
11. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Valve Devices Market: Analysis By Procedure, Replacement Procedure By Technique, Repair ... their offering. ... Global Heart Valve Devices Market is forecasted to grow at a ... heart valve devices is driven by rising aging population, growth in ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... 2017 Summary ... pipeline guide Primary Hyperoxaluria - Pipeline Review, H1 ... (Genito Urinary System And Sex Hormones) pipeline landscape. ... by recurrent kidney and bladder stones. It results ... Symptoms include blood in the urine, pain when ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center PA ... Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite 440, ... newest location will provide patients living in the north Houston area (The Woodlands, Conroe, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing ... a huge impact on businesses and individual consumers alike. Laboratories can maximize their ... a value anywhere from $4 trillion to $11 trillion dollars by the year 2025. ...
Breaking Medicine News(10 mins):